Next-gen sequencing, mass spec to be used in PTSD consortium work

08/13/2013 | GenomeWeb Daily News (free registration)

The STRONG STAR Consortium to Alleviate PTSD, also known as the STRONG STAR-CAP, will use next-generation sequencing to look at structural contributors in diagnosing and treating PTSD, as well as mass spectrometry to discover protein biomarkers that could help predict PTSD risk. The consortium, led by the University of Texas Health Science Center in San Antonio, is receiving a $45 million grant from the Defense Department and Department of Veterans Affairs to support the research.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC